

- I. AMENDMENTS

Please amend the subject application as follows:

In the Specification:

Page 6, line 12, delete "introduces" and insert --induces--, line 18, change "yellow" to --white-- and "red" to --gray--, line 27, change "green" to --white-- and line 29, change "red" to --gray--.

In the Claims:

Please cancel claims 7-20, 22, 25-28 and 33-36 without prejudice.

Please amend the following claims:

- Sub 51*
1. (Twice Amended) An isolated FADD protein [characterized by having the ability to bind the cytoplasmic region of a Fas receptor] comprising the amino acid sequence shown in SEQ ID NO:2, and analogs thereof having conservative amino acid substitutions.
2. (Amended) Purified mammalian protein of claim [1] 53.
3. (Amended) A polypeptide fragment of the protein of claim 1, comprising amino acid 24 to amino acid 208 and analogs thereof having conservative amino acid substitutions.
4. (Amended) The polypeptide of claim [3] 1, wherein the polypeptide consists of at least the C-terminal portion of the protein, and analogs thereof having conservative amino acid substitutions.

Sub 2
D 2
5. (Amended) The polypeptide of claim [3] 1, wherein the polypeptide consists of at least the N-terminal portion of the protein and [characterized by having the ability to induce apoptosis in a suitable cell] analogs thereof having conservative amino acid substitutions.

6. (Twice Amended) A FADD protein or polypeptide of any claims 1-5, which has been recombinantly produced and isolated from a host cell.

D 2
Sub 8
22
21. (Twice Amended) A process for chemically synthesizing a FADD protein or polypeptide, which comprises providing the amino acid sequence of the protein or polypeptide of any of claims 1-5, [to be synthesized] and chemically linking the amino acids in an orientation and under suitable conditions so as to produce the protein or polypeptide.

D 3
23. (Amended) The protein or polypeptide produced by the process of claim [20] 21.

24. (Amended) The protein or polypeptide produced by the process of claim [36] 53.

Please add new claims 37 to 53 as follows:

Sub 4
D 4
37. (New) A polypeptide fragment of claim 1, comprising amino acid 41 to amino acid 208 and analogs thereof having conservative amino acid substitutions.

38. (New) A polypeptide fragment of claim 1, comprising amino acid 111 to amino acid 177 and analogs thereof having conservative amino acid substitutions.

39. (New) A polypeptide fragment of claim 1, comprising amino acid 35 to amino acid 208 and analogs thereof having conservative amino acid substitutions.

40. (New) A polypeptide fragment of claim 5, comprising amino acid 1 to amino acid 117 and analogs thereof having conservative amino acid substitutions.

41. (New) A polypeptide fragment of claim 1, comprising amino acid 41 to amino acid 117 and analogs thereof having conservative amino acid substitutions.

42. (New) A polypeptide fragment of claim 1, comprising amino acid 61 to amino acid 208 and analogs thereof having conservative amino acid substitutions.

43. (New) A polypeptide fragment of claim 1, comprising amino acid 80 to amino acid 208 and analogs thereof having conservative amino acid substitutions.

44. (New) A FADD protein or polypeptide comprising the polypeptide selected from the group consisting of amino acids 111 to 116, 140 to 144, 146 to 160, 164 to 178, and combinations thereof.

45. (New) A FADD mutin protein comprising the amino acid sequence shown in SEQ ID NO: 2 and having asparagine at amino acid 121 and analogs thereof having conservative amino acid substitutions at amino acids 1 to 120 and 123 to 208.

46. (New) A fusion protein comprising the protein or polypeptide of any of claims 1-5.

47. (New) A fusion protein comprising the protein or polypeptide of claim 6.

48. (New) A composition comprising a FADD protein or polypeptide of any of claims 1-5 and a carrier.

49. (New) The composition of claim 48, wherein, the carrier is selected from the group consisting of a detectable label, an adjuvant, a solid support, a stabilizer, a preservative and a pharmaceutically acceptable carrier.

24

50. (New) A composition comprising a FADD protein or polypeptide of claim 6 and a carrier.

51. (New) The composition of claim 50, wherein, the carrier is selected from the group consisting of a detectable label, an adjuvant, a solid support, a stabilizer, a preservative and a pharmaceutically acceptable carrier.

52. (New) The FADD protein or polypeptide of claim 6, wherein the host cell is a procaryotic cell.

53. (New) A process for purifying a FADD protein or polypeptide comprising contacting a sample suspected of containing the FADD protein or polypeptide with a protein or polypeptide comprising the cytoplasmic domain of Fas under conditions suitable for the Fas-containing protein or polypeptide to bind the FADD protein or polypeptide to form a complex, isolating any Fas-FADD complex formed.

In the Figures:

Attached to this response are seventeen (17) pages of formal drawings.

II. REMARKS

Claims 1 to 36 are pending in this application. By this Amendment and response, claims 1-6 and 24 have been amended. Claims 37 to 53 have been added. Claims 7-20, 22, 25 to 28 and 33 to 36 have been canceled without prejudice or disclaimer. The cancellation of these claims and the amendment of claims 1-6 and 24 are not intended as a dedication to the public of the subject matter of the originally filed claims. Applicants expressly reserve their right to file one or more applications directed to the same or similar subject matter under 35 U.S.C. § 120.